127. Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.".
作者: Azmil H Abdul-Rahim.;Ana-Cristina Perez.;Rachael L Fulton.;Pardeep S Jhund.;Roberto Latini.;Gianni Tognoni.;John Wikstrand.;John Kjekshus.;Gregory Y H Lip.;Aldo P Maggioni.;Luigi Tavazzi.;Kennedy R Lees.;John J V McMurray.
来源: Circulation. 2015年132卷22期e358页 128. Letter by Lin et al Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.".129. Response to Letter Regarding Article, "Sudden Cardiac Arrest During Sports Activity in Middle Age".
作者: Eloi Marijon.;Audrey Uy-Evanado.;Kyndaron Reinier.;Carmen Teodorescu.;Kumar Narayanan.;Xavier Jouven.;Karen Gunson.;Jonathan Jui.;Sumeet S Chugh.
来源: Circulation. 2015年132卷22期e356页 134. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.
作者: Matthew J Mitten.;Douglas P Zipes.;Barry J Maron.;William J Bryant.; .
来源: Circulation. 2015年132卷22期e346-9页 135. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology.136. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 12: Emergency Action Plans, Resuscitation, Cardiopulmonary Resuscitation, and Automated External Defibrillators: A Scientific Statement From the American Heart Association and American College of Cardiology.137. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
作者: N A Mark Estes.;Richard J Kovacs.;Aaron L Baggish.;Robert J Myerburg.; .
来源: Circulation. 2015年132卷22期e330-3页 138. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology.
作者: Douglas P Zipes.;Mark S Link.;Michael J Ackerman.;Richard J Kovacs.;Robert J Myerburg.;N A Mark Estes.; .
来源: Circulation. 2015年132卷22期e315-25页 139. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology.
作者: Paul D Thompson.;Robert J Myerburg.;Benjamin D Levine.;James E Udelson.;Richard J Kovacs.; .
来源: Circulation. 2015年132卷22期e310-4页 140. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology.
作者: Alan C Braverman.;Kevin M Harris.;Richard J Kovacs.;Barry J Maron.; .
来源: Circulation. 2015年132卷22期e303-9页 |